Wednesday, 27 January 2021, 7:57 am
Results of the Antibody Mediated Prevention (AMP) studies
to be presented at the IAS HIV Research for Prevention
(HIVR4P // Virtual) conference.
Tuesday, 26
January, 2021 (Geneva, Switzerland) IAS – the
International AIDS Society – welcomes new results from two
proof-of-concept studies (HVTN 704/HPTN 085 and HVTN
703/HPTN 081- the AMP Studies) demonstrating that infusions
of the broadly neutralizing monoclonal HIV antibody (bNAb)
VRC01 can prevent some HIV infections.
The AMP results include
data from more than 4,600 participants in two studies that
enrolled HIV-negative men and transgender people who have
sex with men in the U.S., Brazil and Peru (HVTN 704/HPTN
Results will inform development of long-acting antibody-based HIV prevention tools.
Scanning electromicrograph of an HIV-infected T cell. NIAID
An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The studies are being conducted jointly by the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN).
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
Clinical Trial is Part of the Company’s HIV-1 Prevention Clinical Program Studying Islatravir as a Long-Acting PrEP Agent The company’s investigational oral nucleoside reverse transcriptase translocation inhibitor for pre-exposure prophylaxis . Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied . In the interim … Clinical Trial is Part of the Company’s HIV-1 Prevention Clinical Program Studying Islatravir as a Long-Acting PrEP Agent
The company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI)for pre-exposure prophylaxis (PrEP). Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the t
Wednesday, 27 January 2021, 7:53 am
26 January 2021 – Important advances in HIV prevention
research were announced today at the 4th
HIV Research for Prevention Conference (HIVR4P //
Virtual), convened by IAS – the International AIDS
Society.
Highlights included findings from a pair of
trials evaluating whether infusions with a broadly
neutralizing antibody (bNAb) can prevent HIV acquisition and
positive interim results from a study of long-acting
injectable pre-exposure prophylaxis (PrEP) in women. Other
announcements included promising data from a study of
islatravir as a once-monthly PrEP pill, a study warning that
many African countries are not on track to meet key UNAIDS
prevention targets, new data on global uptake of PrEP, and a
Share
A large study in 11 countries tested whether infusions of monoclonal antibodies against HIV could protect people from infection. HIV Vaccine Trials Network
Labmade antibodies can prevent HIV infection but only if they match the virus
Jan. 26, 2021 , 10:05 AM
It has taken more than 4 years and $119 million for HIV researchers to test whether giving people infusions of antibodies made in a lab can protect them from the AIDS virus. Now, the unsatisfying answer is in: sometimes.
People who were given infusions of the monoclonal antibodies every 8 weeks had a 75% lower risk of becoming infected with HIV but only if they were exposed to strains of the virus that remained susceptible to the antibody. Researchers say the strategy, which they hoped would provide “passive immunity” in contrast to the active immunity triggered by vaccines, none of which exist for the AIDS virus is likely to be more successful with recently developed monoclonal antibodies that work agains